Progyny, Inc. Stock Price, News & Analysis

Progyny, Inc. (Nasdaq: PGNY) is set to release its financial results for the quarter ending September 30, 2021, on November 4, 2021, after market close. A conference call will follow at 4:45 PM ET, during which the company will discuss its results. Participants can join by dialing the provided numbers. An audio replay will be available until November 11, 2021. Progyny specializes in fertility and family-building benefits, focusing on comprehensive solutions that benefit employers, patients, and healthcare providers.

Progyny, a leader in fertility benefits management, announced that CEO David Schlanger and CFO Mark Livingston will participate in a fireside chat at the BofA Global Healthcare Conference on September 15, 2021, at 10:55 A.M. ET. The event will be accessible via a live audiocast on Progyny’s website. Progyny aims to redefine fertility and family building benefits, enhancing access to comprehensive care and reducing healthcare costs for employers. The company has received multiple recognitions for its growth and leadership.

Castlight Health (NYSE: CSLT) has announced the addition of four new partners to its digital health ecosystem, aimed at addressing employee health challenges intensified by the pandemic. The new partners include Spring Health, WW, SWORD Health, and Progyny (NASDAQ: PGNY), enhancing Castlight's offerings in mental health, weight management, and fertility solutions. These partnerships will provide a unified platform for employers to support workforce health, improving engagement through integrated services and two-way data sharing, which typically boosts engagement by 45-55%.

Progyny, a prominent fertility benefits management company, announces that CEO David Schlanger will participate in a fireside chat at the BofA Securities SMID Cap 2H21 Ideas Conference on August 10, 2021, at 1:00 PM ET. A live audiocast and replay will be accessible on Progyny's website. Progyny aims to enhance fertility solutions for employers and patients through dedicated support and a network of specialists. The company has received accolades for its growth and innovation in the healthcare sector.

Progyny, Inc. (PGNY) reported record second quarter revenue of $128.7 million, reflecting a remarkable 99% growth year-over-year. The surge in demand for fertility benefits led to increased client numbers, with 182 clients as of June 30, 2021. Gross profit reached $29.6 million, a 148% increase, while net income soared to $18.7 million, compared to a loss in the prior year. The company anticipates revenue of $510 million to $530 million for the full year 2021, marking a projected 48% to 54% growth.

Progyny (Nasdaq: PGNY), a leader in fertility benefits management, will report its financial results for the quarter ended June 30, 2021, on August 5, 2021. The results will be disclosed after market close, followed by a conference call at 4:45 PM Eastern Time. U.S. participants can access the call by calling 1.866.825.7331, while international callers may use 1.973.413.6106. An audio replay will be available until August 12, 2021. Progyny aims to redefine fertility solutions, benefiting employers, patients, and physicians.

Progyny, a leader in fertility benefits management, announced participation in the Goldman Sachs 42nd Annual Global Healthcare Conference on June 9, 2021, at 3:50 PM ET. CEO David Schlanger and CFO Mark Livingston will engage in a fireside chat, highlighting the company's innovative approach to family building benefits. A live audiocast will be accessible via the Events and Presentations section on Progyny's website. Progyny is recognized for redefining fertility solutions, benefiting patients and employers while driving clinical outcomes.

Progyny, Inc. (Nasdaq: PGNY) partnered with RMA of Connecticut, RMA of New York, and Stanford University to conduct the largest study focusing on single or coupled intended fathers using assisted reproductive technology (ART). The multi-center study analyzed 119 participants and highlighted that 95.2% desired at least 2 children and 72.5% planned to use an egg donor agency. Key findings presented at two conferences showed that SCIFs had an 85.2% success rate for live births when using specific treatment strategies. The study emphasizes the growing demand for fertility treatments among this demographic and the need for comprehensive employer support.

Welltok has integrated Maven and Progyny into its Connect Partner Ecosystem, enhancing employer offerings for family planning and fertility benefits. The inclusion aims to attract and retain talent by providing comprehensive fertility programs. Maven delivers personalized maternity support, resulting in a 90% return-to-work rate and 32% fewer NICU admissions. Progyny boasts a 25% higher live birth rate than national averages and significantly reduces healthcare costs. This partnership underscores Welltok's commitment to improving maternal health and supporting diverse family-building needs.